The SCDM CCDM Questions & Practice Test are Available On-Demand
Valid CCDM Exam Dumps Ensure you a HIGH SCORE
SCDM CCDM Exam Syllabus Topics:
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
| Topic 3 |
|
| Topic 4 |
|
| Topic 5 |
|
NEW QUESTION # 38
A study takes body-composition measurements at baseline using a DEXA scanner. Which information is needed to correctly associate the body-composition data to the rest of the study data?
- A. Study number and visit number
- B. Subject number
- C. Study number and subject number
- D. Subject number and visit number
Answer: D
Explanation:
To properly associate body-composition data (from a DEXA scanner) with other study data, both the subject number and the visit number are required.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), every clinical data record must be uniquely identifiable and linkable to a specific subject and study event. The subject number identifies the participant, while the visit number defines the temporal context in which the measurement was taken.
Without both identifiers, data integration becomes ambiguous-especially if multiple assessments occur over time (e.g., baseline, week 12, end of study). Including both ensures data traceability, integrity, and alignment with the protocol-defined schedule of events.
Study number (option A) alone does not distinguish between visits or subjects, and visit number alone (option C) lacks linkage to the individual participant.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 4.4 - Data Linking and Identification Requirements ICH E6 (R2) GCP, Section 5.5.3 - Data Traceability Principles FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Identification Requirements
NEW QUESTION # 39
Which of the following laboratory findings is a valid adverse event reported term that facilitates auto coding?
- A. Increased alkaline phosphatase, increased SGPT, increased SGOT, and elevated LDH
- B. Abnormal SGOT
- C. ALT
- D. Elevated HDL
Answer: D
Explanation:
When coding adverse events (AEs) using MedDRA (Medical Dictionary for Regulatory Activities), valid AE terms must correspond to specific, medically meaningful concepts that match directly to a Preferred Term (PT) or Lowest Level Term (LLT) in the dictionary.
Among the options, "Elevated HDL" (High-Density Lipoprotein) represents a single, medically interpretable, and standard term that can directly match to a MedDRA LLT or PT. This makes it suitable for auto-coding, where the system automatically maps verbatim terms to MedDRA entries without manual intervention.
In contrast:
ALT (B) and Abnormal SGOT (C) are incomplete or nonspecific; they describe test names or qualitative interpretations rather than events.
Option D lists multiple findings, making it too complex for automatic mapping. Such compound entries would require manual coding review.
According to GCDMP (Chapter: Medical Coding and Dictionaries), a valid AE term should be:
Clinically interpretable (not just a lab test name)
Unambiguous
Single-concept based, not a collection of results
Thus, option A (Elevated HDL) is correct, as it aligns with MedDRA's single-concept, standard terminology structure suitable for auto-coding.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Medical Coding and Dictionaries, Section 5.3 - Auto-coding and Verbatim Term Management ICH M1 MedDRA Term Selection: Points to Consider, Section 2.1 - Coding Principles ICH E2B(R3) - Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports
NEW QUESTION # 40
On a dose escalation study, the Data Manager notices one site has a much higher number of queries than other sites and most are older than 30 days. The Data Safety Monitoring Board will meet in three weeks. What should the Data Manager providing CRO oversight do?
- A. Consult the CRO's Lead Data Manager and the CRO's Project Leader
- B. Call the site directly and ask the study coordinator about the concerns
- C. Ignore it for now and check back next week
- D. Notify the CRO's Clinical Leader about the concerns
Answer: A
Explanation:
The correct action is to consult the CRO's Lead Data Manager and CRO's Project Leader (Option C) to ensure the issue is addressed through the appropriate oversight and escalation process.
According to the GCDMP (Chapter: Project Management and Communication), when a sponsor Data Manager identifies significant data management issues under CRO oversight - such as aging queries or site performance disparities - communication must follow the established governance and escalation pathway defined in the Scope of Work (SOW) and Data Management Plan (DMP).
Directly contacting the site (Option B) bypasses the CRO's chain of command and violates communication protocols. Notifying only the Clinical Leader (Option A) is insufficient, and ignoring the issue (Option D) jeopardizes the Data Safety Monitoring Board (DSMB) review timeline.
Therefore, Option C ensures a documented, collaborative approach to problem resolution within the contractual oversight structure.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Project Management and Communication, Section 7.1 - Oversight of CRO Data Management Activities ICH E6 (R2) GCP, Section 5.2 - Contract Research Organization Responsibilities FDA Guidance for Industry: Oversight of Clinical Investigations - Sponsor and CRO Roles and Communication Pathways
NEW QUESTION # 41
For a study, body mass index is calculated from weight and height. Which information is needed to document the transformation?
- A. Algorithm and algorithm version associated with the calculated value
- B. Algorithm documented in the Data Management Plan
- C. User ID making the change and reason for change
- D. Algorithm associated with the calculated value
Answer: A
Explanation:
When derived or calculated variables (like Body Mass Index) are created, it is essential to document the algorithm used and its version to ensure full data traceability and reproducibility.
According to GCDMP (Chapter: Database Design and Derived Data), every derived field must include metadata describing:
The derivation algorithm (e.g., BMI = weight [kg] / height² [m²])
The version of the algorithm (if updates or revisions occur)
Any associated data sources or transformation rules
This ensures consistent calculation across systems, prevents discrepancies during regulatory submissions, and aligns with FDA and CDISC documentation expectations.
Option B lacks version control, which is critical for traceability. Option C describes audit trail data (not derivation metadata), and option D refers to broader documentation, not specific algorithm traceability.
Hence, option A (Algorithm and algorithm version associated with the calculated value) is the correct and compliant answer.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Derived Data and Algorithms, Section 5.3 - Documentation and Metadata Requirements ICH E6(R2) GCP, Section 5.5.3 - Derived Data and Validation Traceability FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format - Data Definitions (Define.xml)
NEW QUESTION # 42
A Data Manager receives an audit finding of three different instances of simultaneous log-ins to the EDC system by the same site user. This was observed at three different sites. Which of the following is the best long-term response to the audit finding?
- A. Requesting that the sites fire the offending users for a HIPAA violation and increasing the monitoring for the offending sites
- B. Removing all access to the system until the situation is resolved
- C. Refresher training for the offending users, re-communication of the binding nature of e-signatures to all users, routine monitoring for simultaneous log-ins from the same user
- D. Acquiring technical controls from the same or a different system vendor that prevent simultaneous log-ins from the same user
Answer: C
Explanation:
The best long-term corrective and preventive action (CAPA) in this situation is a combination of user re-training, communication, and routine monitoring - as described in Option B.
According to the GCDMP (Chapter: Electronic Data Capture Systems) and FDA 21 CFR Part 11, user credentials and electronic signatures in clinical systems are legally binding and must be used only by the assigned individual. Simultaneous log-ins under the same credentials often indicate credential sharing, a compliance violation that must be addressed through user education, reinforced security policies, and ongoing system oversight.
While technical controls (option A) may be considered, behavioral and procedural reinforcement are the first lines of defense. Options C and D are excessive and not aligned with proportional CAPA practices.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 7.1 - User Access, Authentication, and Training FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures, Sections 11.10(i) and 11.200(a) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Access Control and Audit Trail Requirements
NEW QUESTION # 43
The Scope of Work would answer which of the following information needs?
- A. To find the name and contact information of a specific clinical data associate
- B. To look up which visit PK samples are taken
- C. To determine the number of data transfers budgeted for a project
- D. To look up the date of the next clinical monitoring visit for a specific site
Answer: C
Explanation:
The Scope of Work (SOW) is a project management document that defines what services are included in the work agreement between the sponsor and the CRO or vendor. It outlines deliverables, responsibilities, timelines, and budget allocations.
According to the GCDMP (Chapter: Project Management in Data Management), the SOW includes specifications such as:
The number and frequency of data transfers,
Database build and lock milestones,
Quality control deliverables, and
Resource allocation for data management tasks.
The SOW does not cover operational site-level details such as monitoring schedules (B), protocol sampling details (C), or personnel contact lists (D).
Therefore, option A (number of data transfers budgeted for a project) correctly identifies a use case directly addressed in the SOW.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management, Section 4.1 - Scope of Work and Resource Planning ICH E6(R2) GCP, Section 5.5 - Sponsor Oversight and Data Management Responsibilities PMI Project Management Framework - Scope Definition and Deliverable Specifications
NEW QUESTION # 44
Which Clinical Study Report section would be most useful for a Data Manager to review?
- A. Rationale for the study design
- B. Description of statistical analysis methods
- C. Description of how data were processed
- D. Clinical narratives of adverse events
Answer: C
Explanation:
The section of the Clinical Study Report (CSR) most useful for a Data Manager is the description of how data were processed.
According to the GCDMP (Chapter: Data Quality Assurance and Control), this section details the data handling methodology - including data cleaning, coding, transformation, and derivation procedures - all of which are core responsibilities of data management. Reviewing this section ensures that the data processing methods documented in the CSR align with the Data Management Plan (DMP), Data Validation Plan (DVP), and database specifications.
The statistical methods section (option A) is primarily for biostatistics, and the rationale for study design (option B) pertains to clinical and regulatory affairs. Clinical narratives (option D) are used by medical reviewers, not data managers.
By reviewing how data were processed, the Data Manager verifies that the study data lifecycle-from collection to analysis-was conducted in compliance with regulatory and GCDMP standards.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 6.3 - Documentation of Data Processing in Clinical Study Reports ICH E3 - Structure and Content of Clinical Study Reports, Section 11.3 - Data Handling and Processing FDA Guidance for Industry: Clinical Study Reports and Data Submission - Data Traceability and Handling Documentation
NEW QUESTION # 45
What is the purpose of providing the central laboratory vendor with a complete listing of subjects' demographic data?
- A. To assure that lab data for screening failure subjects have not been included in the lab data transmission
- B. To provide for an independent reconciliation of the patient and remote databases during study conduct
- C. To provide for an independent reconciliation of the patient and remote databases after database lock
- D. To assure that all subjects have lab data for valid visits
Answer: B
Explanation:
Providing the central laboratory vendor with a complete subject demographic listing allows ongoing reconciliation between the sponsor's EDC system and the vendor's laboratory database during study conduct.
The GCDMP (Chapter: External Data Transfers and Integration) emphasizes that subject reconciliation ensures that all laboratory data correspond to valid enrolled subjects and visits. Regular reconciliation throughout the study prevents data mismatches, missing results, or misassigned lab reports.
This proactive measure supports timely query resolution and data integrity across systems. Waiting until after database lock (as in option A) would delay corrections and risk inconsistencies. Options B and D address secondary benefits but not the primary purpose-ongoing subject-level reconciliation.
Thus, option C is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers, Section 4.4 - Reconciliation and Vendor Communication ICH E6(R2) GCP, Section 5.5.3 - Data Management, Reconciliation, and Integration FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - External Data Management
NEW QUESTION # 46
A group of researchers is planning an investigator-initiated study. Assuming that SOPs are not available, which is the best approach for documentation of data management in the planned study?
- A. A Data Management Plan (DMP) template should be developed and a study DMP should be created
- B. Data handling should be documented in a data management plan
- C. Data management related activities should be briefly described in the study protocol
- D. Data management SOPs must be developed prior to initiation of study
Answer: A
Explanation:
In the context of an investigator-initiated trial (IIT) where Standard Operating Procedures (SOPs) are not available, the most appropriate and compliant approach is to develop a Data Management Plan (DMP) template and then create a study-specific DMP based on that template (Option C).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Management Planning and Study Start-up), the DMP is the central document that defines all processes, responsibilities, systems, and quality controls related to data collection, processing, validation, and database management throughout the clinical study. The DMP serves as a formal framework for ensuring data integrity, traceability, and regulatory compliance, especially in the absence of established institutional SOPs.
While SOPs provide organizational-level standards, the DMP provides study-specific operational detail. In an investigator-initiated setting, researchers often lack institutional data management infrastructure, so the DMP must substitute for SOP guidance by detailing:
Data entry and validation procedures
Query management and resolution processes
CRF design and data flow specifications
Database design, backup, and security
Responsibilities of study personnel (investigator, data manager, statistician) Quality control and audit trail practices Option A ("Data handling should be documented in a DMP") is correct in principle but incomplete-without a DMP template, there is no standardized format or consistency across studies.
Option B (developing full SOPs) is not practical for a single IIT; SOPs are organizational-level documents requiring longer development and approval cycles.
Option D (briefly describing data management in the protocol) is insufficient, as the protocol should reference data management activities but not serve as the operational manual for them.
Therefore, Option C provides the most comprehensive, regulatory-compliant, and practical solution-ensuring structured documentation of all data management activities while maintaining flexibility for investigator-led research.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 5.2 - Data Management Plan (DMP) Development and Maintenance ICH E6 (R2) Good Clinical Practice, Section 5.1 - Quality Management and Documentation Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 4 - Data Management and Documentation Practices SCDM GCDMP, Chapter: Project Management in Data Management - Study-Specific Documentation and Planning in Investigator-Initiated Trials
NEW QUESTION # 47
Based on the project Gantt chart as of 01 Nov 2019, an interim analysis is scheduled to occur early Q2 of 2020. All of the following are valid for initially assessing the status of data cleanliness EXCEPT:
- A. Identifying all outstanding discrepancies to date and aging
- B. Determining CRF data entry status of received pages
- C. Identifying missing pages where visits have been completed to date
- D. Identifying the number of discrepancies resolved to date
Answer: D
Explanation:
When initially assessing data cleanliness in preparation for an interim analysis, the focus should be on outstanding issues that could affect data completeness and reliability.
According to the GCDMP (Chapter: Data Quality Assurance and Control), key indicators of readiness include:
The CRF data entry status of received pages (option A) to confirm completeness.
Identification of missing pages or visits (option B) to verify subject-level completeness.
A listing of outstanding discrepancies and their aging (option D) to assess unresolved data issues.
Counting the number of discrepancies resolved to date (option C), however, does not reflect data quality or current data readiness-it indicates past actions rather than current unresolved risks. Therefore, it is not a valid measure for assessing interim data cleanliness.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 6.1 - Data Readiness Assessments for Analysis ICH E6 (R2) GCP, Section 5.18.4 - Ongoing Data Quality Review FDA Guidance for Industry: Oversight of Clinical Investigations - Risk-Based Monitoring, Section 7 - Data Quality Indicators
NEW QUESTION # 48
The primary reason for system validation is to:
- A. Fulfill the validation plan.
- B. Meet regulatory requirements.
- C. Prove the system being tested works as intended.
- D. Allow a system to be used by its intended users.
Answer: C
Explanation:
The primary purpose of system validation in clinical data management is to demonstrate and document that the computerized system performs as intended-accurately, reliably, and consistently-throughout its lifecycle.
According to the Good Clinical Data Management Practices (GCDMP, Chapter on System Validation) and FDA 21 CFR Part 11, validation ensures that all system functions (e.g., data entry, edit checks, audit trails, security) work as designed, providing data integrity, traceability, and regulatory compliance. The focus is on fitness for intended use, meaning the system reliably produces correct and reproducible results in the context of its operational environment.
While meeting regulatory requirements (option C) and fulfilling a validation plan (option B) are components of the process, they are not the ultimate purpose. The essential goal is ensuring that the system performs as intended, maintaining accuracy and data integrity for clinical trial operations.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Computerized Systems and System Validation, Section 5.2 - Purpose and Scope of System Validation FDA 21 CFR Part 11 - Validation of Computerized Systems for Intended Use ICH E6(R2) GCP, Section 5.5.3 - Computerized System Validation and Data Integrity
NEW QUESTION # 49
What is the main reason 21 CFR Part 11 requires that EDC systems maintain an audit trail?
- A. To preserve source document verifications
- B. To preserve data integrity
- C. To preserve data availability
- D. To preserve the ability for modifications
Answer: B
Explanation:
The primary purpose of maintaining an audit trail as required under 21 CFR Part 11 is to preserve data integrity. According to the U.S. FDA's regulation on electronic records and signatures, every change to electronic data must be traceable, including information about who made the change, when it was made, and what the change entailed.
The Good Clinical Data Management Practices (GCDMP) outlines that an audit trail provides a permanent, chronological record of all modifications to clinical data. This ensures transparency and allows the reconstruction of the course of data entry and modification. The regulation aims to prevent unauthorized or undocumented data manipulation, thereby maintaining the accuracy, reliability, and validity of electronic records.
The FDA 21 CFR Part 11, Section 11.10(e) explicitly mandates that systems must use secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. This ensures the data remains trustworthy and defensible in regulatory reviews or inspections.
Therefore, the main reason for requiring an audit trail is to preserve data integrity - ensuring that all data captured, modified, or transmitted is authentic, accurate, and complete throughout the study lifecycle.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Compliance and Data Integrity FDA 21 CFR Part 11 - Electronic Records; Electronic Signatures, Section 11.10(e) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Integrity and System Validation
NEW QUESTION # 50
Which Clinical Study Report section would be most useful for a Data Manager to review?
- A. Enumeration and explanation of data errors
- B. Rationale for the study design
- C. Description of statistical analysis methods
- D. Clinical narratives of adverse events
Answer: A
Explanation:
The section of the Clinical Study Report (CSR) that is most useful for a Data Manager is the one that includes the enumeration and explanation of data errors. This section provides a summary of the data quality control findings, including error rates, missing data summaries, and any issues identified during data review, validation, or database lock.
According to the GCDMP (Chapter: Data Quality Assurance and Control), post-study reviews of data errors and quality findings are essential for evaluating process performance, identifying recurring issues, and informing continuous improvement in future studies.
Other sections, such as clinical narratives (A) or statistical methods (C), are outside the core scope of data management responsibilities. The data error enumeration section directly reflects the quality and integrity of the data management process and is therefore the most relevant for review.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.4 - Quality Reporting and Error Analysis ICH E3 - Structure and Content of Clinical Study Reports, Section 14.3 - Data Quality Evaluation
NEW QUESTION # 51
Who has primary responsibility for ensuring accurate completion of the CRF?
- A. Clinical Data Manager
- B. Site Coordinator
- C. Clinical Research Associate
- D. Investigator
Answer: D
Explanation:
The Investigator holds the primary responsibility for ensuring the accuracy, completeness, and timeliness of Case Report Form (CRF) entries. This responsibility is mandated by regulatory requirements under ICH E6(R2) Good Clinical Practice (GCP).
The investigator may delegate CRF completion to a qualified designee (e.g., site coordinator), but the ultimate accountability remains with the investigator. The investigator's signature (electronic or manual) on the CRF serves as certification that the data accurately reflect the source documents and the patient's participation.
The GCDMP (Chapter: CRF Design and Data Collection) reinforces this by stating that while data managers ensure design quality and CRAs verify consistency with source data, the investigator is legally responsible for CRF accuracy.
Thus, option D (Investigator) is correct, as it aligns with both GCP and CCDM standards.
Reference (CCDM-Verified Sources):
ICH E6(R2) GCP, Section 4.9 - Records and Reports (Investigator Responsibilities) SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 5.1 - Investigator's Role in Data Accuracy FDA 21 CFR Part 312.62 - Investigator Recordkeeping and Record Retention
NEW QUESTION # 52
What method is used for quality control of the query resolution process?
- A. Tabulate the number of queries sent per site.
- B. Calculate the time from query sent to query resolution from the site.
- C. Perform random audits of the resolved query forms.
- D. Calculate the time from discrepancy identified to query sent.
Answer: C
Explanation:
The most effective method for quality control (QC) of the query resolution process is to perform random audits of resolved query forms. This ensures that queries are being appropriately raised, addressed, and resolved in accordance with the study protocol, data management plan (DMP), and standard operating procedures (SOPs).
According to the GCDMP (Chapter: Data Validation and Cleaning), QC activities should verify that the data review and query management process maintains high accuracy and consistency. Random auditing of resolved queries enables verification that:
Queries were raised for legitimate discrepancies,
The site's responses were appropriate, and
The resolution actions taken by data management were correct and well-documented.
Metrics such as turnaround time (options A and C) or query counts (option B) measure efficiency but do not assess quality. True quality control focuses on ensuring that data corrections preserve accuracy, auditability, and traceability - the fundamental principles of data integrity in clinical research.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 5.4 - Query Management and Quality Control ICH E6 (R2) GCP, Section 5.5.3 - Data Integrity and Validation Procedures
NEW QUESTION # 53
Which list should be provided to support communication with sites regarding late data and queries?
- A. List of subjects screened and enrolled by site
- B. List of entered and clean data by site
- C. List of user account activity by site
- D. List of outstanding data and queries by site
Answer: D
Explanation:
Effective site communication in data management relies on transparent reporting of pending issues such as open queries, missing data, and overdue updates. According to the Good Clinical Data Management Practices (GCDMP, Chapter: Communication and Metrics), the list of outstanding data and queries by site provides a direct, actionable overview of what each site needs to address, supporting accountability and timely resolution.
This list typically includes subject identifiers, query types, dates generated, and status of resolution, allowing data managers to prioritize site follow-ups. Regular distribution of this report fosters efficient collaboration between the data management team, monitors, and site staff, ultimately improving database cleanliness and timeline adherence.
Options A and B reflect general study status but do not target data issue resolution. Option C pertains to user access oversight, not data progress. Hence, option D is the correct and most operationally relevant answer.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Communication and Metrics, Section 5.2 - Site Reporting and Query Management Metrics ICH E6(R2) GCP, Section 5.18 - Site Oversight and Communication Requirements
NEW QUESTION # 54
During testing of an ePRO system, a test fails. Which information should be found in the validation documentation?
- A. Expected and actual results
- B. Reconciliation datapoints
- C. Root cause analysis of the system errors
- D. Training requirements
Answer: A
Explanation:
When a system validation test fails during Electronic Patient-Reported Outcome (ePRO) system testing, the validation documentation must record the expected results (what should have occurred) and the actual results (what occurred).
According to the GCDMP (Chapter: Database Validation and Testing), proper system validation documentation ensures traceability, reproducibility, and compliance with FDA 21 CFR Part 11 and ICH E6 (R2). Each test case must include:
Test objective,
Preconditions,
Test steps,
Expected results,
Actual results, and
Pass/fail status.
If a test fails, this documentation provides the objective evidence necessary for deviation handling, issue resolution, and re-testing. While a separate root cause analysis may be performed later (option D), the validation record itself must focus on verifying outcomes against predefined expectations.
Therefore, the correct answer is B - Expected and actual results.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Validation and Testing, Section 4.4 - Documentation of Test Results FDA 21 CFR Part 11 - Validation Requirements (Section 11.10(a)) ICH E6 (R2) GCP, Section 5.5.3 - Computer System Validation and Documentation
NEW QUESTION # 55
All of the following are preparation processes the data manager needs to take prior to database closure EXCEPT:
- A. Performing SAE reconciliation between the clinical and safety databases.
- B. Ensuring all data expected for the study has been received.
- C. Checking for uncoded terms in all panels that are coded.
- D. Ensuring study close out visits have been complete.
Answer: D
Explanation:
Before database lock, the Data Manager must confirm that all collected data are complete, validated, and reconciled across systems. This includes:
Ensuring data completeness (B) - confirming all expected forms and data files have been received.
Verifying coded data (A) - ensuring no pending terms remain in coding dictionaries like MedDRA or WHO Drug.
Performing SAE reconciliation (C) - cross-checking the clinical database against the safety system for accuracy.
However, ensuring study close-out visits (D) is not a data management function; it falls under clinical operations and monitoring responsibilities. While data management may review confirmation of site close-outs, the activity itself is not part of pre-database lock procedures.
Therefore, option D correctly identifies the exception-an activity outside the data manager's direct scope of responsibility before database closure.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.3 - Pre-Lock Validation and Reconciliation Activities ICH E6(R2) GCP, Section 5.5.3 - Data Handling and Quality Control Prior to Lock FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - Database Management and Lock Procedures
NEW QUESTION # 56
Data characterizing the safety profile of a drug are collected to provide information for which of the following?
- A. Product labeling
- B. Quality of life calculations
- C. Efficacy meta-analyses
- D. Survival curves
Answer: A
Explanation:
Safety data collected during a clinical trial are used primarily to support product labeling, ensuring accurate communication of a drug's risks, contraindications, and adverse reactions to healthcare providers and patients.
According to the GCDMP (Chapter: Safety Data Handling and Reconciliation) and ICH E2A/E2F guidelines, all adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities are analyzed and summarized to define the safety profile of an investigational product. These data form the basis for regulatory submissions such as the Clinical Study Report (CSR) and product labeling (e.g., prescribing information), as required by the FDA and other regulatory authorities.
While safety data may contribute indirectly to analyses such as survival curves (option A) or quality of life metrics (option D), their primary regulatory function is to inform product labeling and post-marketing surveillance documentation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Safety Data Handling and Reconciliation, Section 4.3 - Use of Safety Data in Regulatory Submissions ICH E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting FDA Guidance for Industry: Adverse Event Reporting and Labeling Requirements
NEW QUESTION # 57
What does RACI stand for?
- A. Recommend, Approve, Calibrate, Innovate
- B. Responsible, Accountable, Consulted, Informed
- C. Responsible, Accountable, Contribute, Input
- D. Responsibility, Accountability, Consultation, Information
Answer: B
Explanation:
RACI is a project management and governance framework used to define roles and responsibilities within a project. Each letter represents a distinct role type:
Responsible (R): The person(s) who perform the work or execute the task.
Accountable (A): The individual ultimately answerable for the task's completion and success (only one per activity).
Consulted (C): Subject matter experts who provide input or guidance before decisions are made.
Informed (I): Individuals kept up to date on progress or outcomes but not directly involved in execution.
The RACI model ensures clarity in ownership and accountability, preventing duplication of effort or responsibility confusion. It is a key component of the GCDMP (Chapter: Project Management in Data Management) for ensuring clear delegation and communication within clinical data management teams.
Hence, option D is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management in Data Management, Section 5.1 - Roles, Responsibilities, and RACI Matrices Project Management Institute (PMI) Framework - Responsibility Assignment Matrices (RACI) ICH E6(R2) GCP, Section 5.1.1 - Defined Roles and Quality Oversight Responsibilities
NEW QUESTION # 58
In reviewing the adverse events for a subject, a data manager notices one recorded as "worsening of migraine." After reviewing the rest of the adverse events and finding no other migraine recordings, what is the data manager's next step?
- A. Look for any adverse event instance of headache and assume the events are similar.
- B. Query the site for more information on the adverse event, "worsening of migraine."
- C. Check the medical history for recording of a history of migraines.
- D. Query the site for the first adverse event occurrence of migraine.
Answer: B
Explanation:
When a data inconsistency arises - such as a record of "worsening of migraine" without prior documentation of a migraine episode - the Data Manager should query the site for clarification (Option D).
According to the GCDMP (Chapter: Data Validation and Cleaning), data managers must raise a clarification query whenever data appear incomplete, inconsistent, or ambiguous. The site must confirm whether "worsening of migraine" refers to a new event or an exacerbation of a preexisting condition. This clarification ensures accurate safety reporting and appropriate medical coding (e.g., MedDRA classification).
Checking the medical history (Option C) may help but does not resolve the inconsistency. Assuming a relationship (Option A or B) without verification would violate Good Clinical Data Management Practice and potentially misrepresent the adverse event.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Query Generation and Resolution ICH E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, Section II - Data Clarification Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Query Management
NEW QUESTION # 59
......
CCDM Exam Practice Questions prepared by SCDM Professionals: https://www.fast2test.com/CCDM-premium-file.html
Pass CCDM Exam with Latest Questions: https://drive.google.com/open?id=1589nemgITbq61AMq6lq-4q2z-DoL-7_2